Blair William & Co. IL Acquires 6,237 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Blair William & Co. IL boosted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 15.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,254 shares of the biopharmaceutical company’s stock after buying an additional 6,237 shares during the period. Blair William & Co. IL’s holdings in Amicus Therapeutics were worth $469,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Headlands Technologies LLC bought a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at about $89,000. Sage Capital Advisors llc acquired a new stake in Amicus Therapeutics in the second quarter valued at approximately $103,000. EntryPoint Capital LLC grew its holdings in Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 9,729 shares during the last quarter. Old Well Partners LLC acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth $180,000. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in shares of Amicus Therapeutics during the 1st quarter valued at $225,000.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on FOLD. Jefferies Financial Group assumed coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. JPMorgan Chase & Co. decreased their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 16th. Wells Fargo & Company started coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research note on Friday, September 20th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $10.34, for a total transaction of $77,550.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total transaction of $77,550.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,866,540. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,100 shares of company stock worth $226,375. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $10.72 on Friday. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The company has a market cap of $3.18 billion, a PE ratio of -21.88 and a beta of 0.69. The company’s 50 day moving average is $11.07 and its 200 day moving average is $10.69.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. During the same quarter in the prior year, the business earned ($0.15) earnings per share. The business’s quarterly revenue was up 34.0% compared to the same quarter last year. On average, sell-side analysts forecast that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.